Advanced Biliary Tract Cancer Clinical Trials

5 recruiting

Advanced Biliary Tract Cancer Trials at a Glance

7 actively recruiting trials for advanced biliary tract cancer are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Shanghai, Cleveland, and Columbus. Lead sponsors running advanced biliary tract cancer studies include Dai, Guanghai, Fudan University, and CHA University.

Browse advanced biliary tract cancer trials by phase

Treatments under study

About Advanced Biliary Tract Cancer Clinical Trials

Looking for clinical trials for Advanced Biliary Tract Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Biliary Tract Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Biliary Tract Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Biliary Tract Cancer (BTC)Advanced Biliary Tract Cancer
J-Pharma Co., Ltd.480 enrolled18 locationsNCT07265674
Recruiting

A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain

Advanced Pancreatic CancersAdvanced Biliary Tract Cancer(BTC)Cancer-related Pain
Tongji Hospital103 enrolled1 locationNCT07326137
Recruiting
Phase 3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Advanced Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.604 enrolled1 locationNCT07229625
Recruiting

Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer

Locally Advanced Biliary Tract CancersMetastatic Biliary Tract Cancers
CHA University61 enrolled1 locationNCT06893380
Recruiting
Phase 2

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.46 enrolled1 locationNCT06978114
Recruiting

GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment (BTC-IM-1)

Advanced Biliary Tract Cancer
Fudan University100 enrolled1 locationNCT06988592
Recruiting
Phase 2

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer
Dai, Guanghai35 enrolled1 locationNCT06708858